CTIS2022-502916-35-01招募中1 期
A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer - EDGE-LUNG
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 263
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Histologically confirmed, documented diagnosis of Stage IV metastatic, NSCLC, Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1, At least one measurable target lesion per RECIST v1.1, Adequate organ and bone marrow function, Participants must be willing to provide adequate tumor tissue
排除标准
- •Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of Investigational Product(s) (IPs) hazardous, Use of any live vaccines against infectious diseases within 28 days of first dose of IP(s), Concurrent chronic medical condition requiring the use of supra-physiologic doses of corticosteroids (> 10 mg/day of oral prednisone or equivalent) or immunosuppressive medications (absorbable topical corticosteroids are not excluded), Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial, Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy
研究者
相似试验
进行中（未招募）
1 期
A phase I/II open-label platform study to evaluate the safety and efficacy of multiple amivantamab-based therapeutic combinations in participants with advanced, unresectable lung cancernresectable metastatic non-small cell lung cancerCancerISRCTN23584582Janssen-Cilag International NV201
进行中（未招募）
1 期
Platform trial evaluating safety and efficacy of BI 754091 anti- PD-1 based combination therapies in PD-(L)1 naïve and PD- (L)1 pretreated patient populations with advanced/metastatic solid tumoursAdvanced/metastatic solid tumoursMedDRA version: 21.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 100000004864EUCTR2018-002344-81-GBBoehringer Ingelheim Limited260
招募中
2 期
A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non Small Cell Lung CancerNSCLClung cancerNL-OMON51766GlaxoSmithKline20
招募中
1 期
PH2a, Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated, Advanced/Metastatic NSCLCung Cancer, Non-Small CellCTIS2023-505057-40-00Glaxosmithkline Research & Development Limited280
招募中
1 期
Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckCTIS2023-503428-24-00Glaxosmithkline Research & Development Limited350